Abstract
Schizophrenia is a complex disease whose biology is not completely understood,
a reality that presents a major hurdle to companies developing new therapies
for schizophrenia. As a result, many companies have focused on the development
of agents that, like existing agents, target the serotonin and dopamine
receptors. Thus, over the next several years, emerging treatments for
schizophrenia are expected to function by the same general mechanisms as
existing therapies. How can they distinguish themselves and gain market share?
What strategies will companies working in this field employ to extend the use
and sales of their agents? What are the prospects for development of agents
that work via novel mechanisms? In this report, we provide an overview of the
disease of schizophrenia and discuss currently available drugs and emerging
therapies in late-stage development. Last, we assess the current competition
as well as market prospects and competitive strategies for these agents.
Table of Contents
Introduction
Overview of Schizophrenia
- Disease Symptoms, Onset, and Prevalence
- Pathophysiology and Risk Factors for Schizophrenia
Current Therapies for Schizophrenia
- Typical Antipsychotics
- Atypical Antipsychotics
- A Side-by-Side Comparison: Results from the Clinical Antipsychotic Trials
of Intervention
- Effectiveness (CATIE)
Emerging Therapies for Schizophrenia
- Serotonin and Dopamine Receptor Antagonists
- H. Lundbeck's Serdolect
- Dainippon Sumitomo Pharmaceuticals' Blonanserin
- Johnson & Johnson's Paliperidone
- Organon/Pfizer's Asenapine
- Vanda Pharmaceuticals' Iloperidone
- Dopamine Partial Agonists
- Serotonin Inverse Agonists
- Novel Agents
- Neurokinin Receptor Antagonists
- AMPA Receptor Modulators
- Secretin Antagonists
Current Market and Future Prospects for Schizophrenia Therapies
医薬品
その他のカテゴリ
FAQ